Expecting something from the FDA is a risky endeavor, and that makes it all the more worthwhile to read the tea leaves every once in a while. The agency will struggle to maintain traction in 2012. Congress began second guessing a number of the agency’s actions … Continue reading at ComplianceZen.com →
Menu